- Home
- KFY vs VRDN Comparison
KFY vs VRDN Comparison
Compare KFY & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KFY | VRDN |
|---|---|---|
| Founded | 1969 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | KFY | VRDN |
|---|---|---|
| Price | $60.49 | $28.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $78.00 | $41.42 |
| AVG Volume (30 Days) | 459.8K | ★ 1.5M |
| Earning Date | 03-10-2026 | 02-27-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 5.12 | N/A |
| EPS | ★ 4.91 | N/A |
| Revenue | ★ $2,811,089,000.00 | $70,789,000.00 |
| Revenue This Year | $5.60 | $26,080.80 |
| Revenue Next Year | $4.16 | $2.07 |
| P/E Ratio | $12.71 | ★ N/A |
| Revenue Growth | 3.78 | ★ 23340.07 |
| 52 Week Low | $59.23 | $9.90 |
| 52 Week High | $78.50 | $34.29 |
Technical Indicators
Market Signals| Indicator | KFY | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 32.64 | 34.90 |
| Support Level | $66.53 | $28.92 |
| Resistance Level | $68.31 | $30.75 |
| Average True Range (ATR) | 2.25 | 1.48 |
| MACD | -0.71 | -0.41 |
| Stochastic Oscillator | 3.66 | 8.76 |
Price Performance
Historical ComparisonAbout KFY Korn Ferry
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).